Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes

Satish K. Garg, MD,1 Mark Kipnes, MD,2 Kristin Castorino, DO,3 Timothy S. Bailey, MD,4 Halis Kaan Akturk, MD,1 John B. Welsh, MD, PhD,5 Mark P. Christiansen, MD,6 Andrew K. Balo, BS,5 Sue A. Brown, MD,7 Jennifer L. Reid, PhD,5 and Stayce E. Beck, PhD, MPH5

Abstract

Background: We evaluated the accuracy and safety of a seventh generation (G7) Dexcom continuous glucose monitor (CGM) during 10.5 days of use in adults with diabetes.

Methods: Adults with either type 1 or type 2 diabetes (on intensive insulin therapy or not) participated at 12 investigational sites in the United States. In-clinic visits were conducted on days 1 or 2, 4 or 7, and on the second half of day 10 or the first half of day 11 for frequent comparisons with comparator blood glucose measurements obtained with the YSI 2300 Stat Plus glucose analyzer. Participants wore sensors concurrently on the upper arm and abdomen. Accuracy evaluation included the proportion of CGM values within 15% of comparator glucose levels $>$100 mg/dL or within 15 mg/dL of comparator levels $\leq 100$ mg/dL (%15/15), along with the %20/20 and %30/30 agreement rates. The mean absolute relative difference (MARD) between temporally matched CGM and comparator values was also calculated.

Results: Data from 316 participants (619 sensors, 77,774 matched pairs) were analyzed. For arm- and abdomen-placed sensors, overall MARDs were 8.2% and 9.1%, respectively. Overall %15/15, %20/20, and %30/30 agreement rates were 89.6%, 95.3%, and 98.8% for arm-placed sensors and were 85.5%, 93.2%, and 98.1% for abdomen-placed sensors. Across days of wear, glucose concentration ranges, and rates of change, %20/20 agreement rates varied by no more than 9% from the overall %20/20. No serious adverse events were reported.

Conclusions: The G7 CGM provides accurate glucose readings with single-digit MARD with arm or abdomen placement in adults with diabetes. Clinicaltrials.gov: NCT04794478

Keywords: Continuous glucose monitoring, Dexcom, Accuracy, G7, MARD.

1Department of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
2DGD Clinic, San Antonio, Texas, USA.
3Sansum Diabetes Research Institute, Santa Barbara, California, USA.
4AMCR Institute, Escondido, California, USA.
5Dexcom, Inc., San Diego, California, USA.
6Diablo Clinical Research, Walnut Creek, California, USA.
7University of Virginia, Charlottesville, Virginia, USA.

© Satish K. Garg, et al., 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Introduction

Over the past decade, there have been several advances in diabetes technology such as continuous glucose monitoring (CGM) systems, insulin delivery devices, and hybrid closed-loop systems. CGMs are increasingly used by people with type 1 diabetes (T1D) and type 2 diabetes (T2D), especially those requiring insulin, to improve and maintain good glycemic control.1–4 The currently available G6 CGM (Dexcom, Inc., San Diego, CA, USA) provides accurate readings, as demonstrated in earlier studies in adult5,6 and pediatric7 populations.

The glucose values are provided at 5-min intervals and can be used for diabetes treatment decisions or can be acted upon by devices from other manufacturers, such as automated insulin delivery systems or multidose memory insulin pens. G6 features such as its optional calibrations, predictive alerts, and automated sensor insertions facilitated diabetes management when G6 was introduced >3 years ago.

A seventh generation (G7) CGM (Dexcom) was designed to improve upon the performance and usability aspects of the G6 CGM. Similar to G6, the G7 relies on a subcutaneous glucose oxidase-based sensor that is factory calibrated and allows for optional user-initiated calibrations. Data from either system can be displayed on a dedicated receiver or on a variety of iOS and Android smart devices; both the G6 and the G7 use Bluetooth low energy to transmit data with an obstacle-free range of 20 feet. However, the on-body portion of G7 is 60% smaller than that of G6, and each sensor includes its own single-use transmitter. G7 features several other differences including automatic session initializations, a 27-min warm-up period (vs. 2 h for G6), and a 12-h (half a day) grace period at the end of the sensor’s 10-day working life during which glucose data are still displayed.

If the receiver detects a gap in the data, up to 24 h of missing data can be requested from the wearable portion of the system to display glucose values that were not successfully transmitted at the time of collection. G7, like G6, is not susceptible to interference by acetaminophen or ascorbic acid. Users have the option to customize settings for rate-of-change (RoC) alerts and can disable audible glucose alerts for up to 6 h. G7 also offers real-time remote monitoring (“Sharing”) functionality, which caregivers and providers may find useful.

This multicenter study evaluated the accuracy and safety attributes of G7 in adults with diabetes. The performance of sensors worn on the arm and abdomen was assessed across the 10.5-day wear period, different glucose concentration ranges, and various rates of glucose changes. Adverse events related to sensor insertion, wear, and removal were also reported.

Methods

Study design and participants

This prospective multicenter single-arm study was conducted at 12 sites in the United States. The protocol and consent forms were approved by local and/or centralized institutional review boards. Written informed consent was obtained from each study participant before study initiation.

Between February and June 2021, the study enrolled 318 adults of ages 18–78 years. Participants were eligible if they had T1D, intensive insulin therapy T2D (T2D-IIT), or non-intensive insulin therapy T2D (T2D-NIIT). Participants were recruited without regard to race, gender, or body mass index (BMI). Inclusion criteria included willingness to wear up to three G7 devices for the duration of the study, and willingness to avoid injecting insulin and wearing an insulin pump infusion set within 3 inches of the insertion site. G7 components are shown in Figure 1.

The wearable transmitter measures 24 × 27.3 × 4.6 mm, or roughly the size of three stacked quarters. All subjects
participated in clinic sessions involving venous blood draws. Exclusion criteria included the presence of skin conditions at sensor wear sites, known allergy to medical-grade adhesives, pregnancy, abnormal hematocrit levels, and medical conditions that could compromise patient safety or staff safety (at the investigator’s discretion). Detailed inclusion and exclusion criteria are provided in Supplementary Table S1. The study protocol was reviewed by the Food and Drug Administration through the investigational device exemption process and registered at (clinicaltrials.gov).

**Study procedures**

Each participant wore G7 sensors on the back of the upper arm and on the abdomen. Neither device provided real-time glucose concentrations or alerts to the patients or the research staff during the study. Participants and research teams were not provided with the optional receiver/display component shown in Figure 1. After participants received training on G7, sensor insertions were performed in the clinic by the participants. G7 CGMs that failed within the first 12 h were replaced in the same wear location. Participants completed surveys about the ease of G7 insertion and preferred device wear location.

During home use, participants were advised to continue their usual glucose monitoring practices (blood testing or use of a personal CGM), diabetes management regimens, and activities. Participants were also scheduled for three 12-h clinic sessions on days 1 or 2, days 4 or 7, and the second half of day 10 (hours 228 to 240) or first half of day 11 (hours 240 to 252) of the wear period. During clinic sessions, arterialized venous blood glucose concentrations were determined with the YSI 2300 Stat Plus glucose analyzer (YSI, Inc., Yellow Springs, OH, USA).

Hyperglycemia and hypoglycemia were induced by adjusting the timing or amount of rapid-acting insulin and carbohydrates; the amount of insulin or carbohydrates was based on participants’ usual insulin dosing and meal timing and authorized by the clinical research staff. These per-protocol manipulations were done under close observation by the clinical investigational staff. Blood glucose determinations were made at 15 ± 5-min intervals for YSI values in the 80–300 mg/dL range and at 10 ± 5-min intervals for YSI values that were <80 or >300 mg/dL.

All CGM removals were performed by participants. For participants assigned to a clinic session on the second half of day 10 or first half of day 11, G7 removals were performed after completion of the clinic session. During the removal visit, study staff evaluated insertion sites and adhesive areas, and documented any participant-reported adverse events.

**Data analysis**

To obtain CGM-measured glucose values for analysis, raw sensor signals collected by the transmitter were post-processed using a proprietary algorithm. YSI measurements taken during the clinic sessions were matched with the first available CGM value obtained within the subsequent 5 min, including only CGM values within the 40–400 mg/dL reportable range. Sensors that failed before a subject’s first clinic session were excluded from the analysis.

Accuracy metrics included %15/15 (the proportion of CGM values that were within 15% of paired YSI values >100 or 15 mg/dL of YSI values ≤100 mg/dL), as well as %20/20 and %30/30 agreement rates, the mean absolute difference (MAD), and the mean absolute relative difference (MARD) of each CGM-YSI pair. MAD is given in units of glucose concentration and is appropriate for YSI values in the low range, where relative differences may be large. For higher YSI values where absolute differences may be large, MARD is given as a percent and is calculated as the mean ratio of the absolute difference between each CGM-YSI pair and the YSI value.

For analysis of accuracy across CGM glucose ranges, MAD is presented for CGM values ≤80 mg/dL and MARD is presented for CGM values >80 mg/dL. Sensor heterogeneity was assessed by analyzing each sensor’s MARD and by determining the proportion of sensors having >80% of their values meet the %20/20 accuracy criterion. Performance was assessed across glucose concentration ranges and days of sensor wear. Heterogeneity of accuracy within patient subgroups was analyzed using a generalized estimating equations model to adjust for intrasubject correlation.

Accuracy was also analyzed at various CGM rates of glucose concentration change. RoC was calculated as the difference between consecutive glucose values per unit of time, in units of mg/dL per minute. MARD and %20/20 were evaluated for the following RoC categories: <-2, -2 to <-1, -1 to <0, 0 to 1, >1 to 2, and >2.

G7 detection of hypoglycemia and hyperglycemia was evaluated by identifying CGM values surrounding YSI values in <70 and >250 mg/dL ranges. The analyses were conducted assuming that the G7 low and high alert thresholds were set to 55 and 300 mg/dL, respectively. True hypoglycemia alerts were those accompanied within 15 min by YSI value(s) <70 mg/dL; similarly, true hyperglycemia alerts were those accompanied by YSI value(s) >250 mg/dL.

Separately, more stringent criteria for hypoglycemic and hyperglycemic alerts and detections were applied. For alerts, YSI values within 15 min of an out-of-range CGM value were considered, and for detections, CGM values within 15 min of an out-of-range YSI value were considered. For the hypoglycemic alert rate, a CGM value below a specific threshold was considered a hypoglycemic alert; it was considered a true alert if at least one YSI value within the 15-min window was also below the specified threshold. For the hyperglycemic alert rate, a CGM value above a specific threshold was considered a hyperglycemic alert; it was considered a true alert if at least one YSI value within the 15-min window was also above the specified threshold.

For the hypoglycemic detection rate, a YSI value below a specific threshold was considered a hypoglycemic event; it was considered a true detection if at least one CGM value within the 15-min window was also below the specified threshold. For the hyperglycemic detection rate, a YSI value above a specific threshold was considered a hyperglycemic event; it was considered a true detection if at least one CGM value within the 15-min window was also above the specified threshold. G7 Urgent Low Soon alerts, identical to those of G6, were triggered by downward trends in CGM values predicted to progress to CGM value(s) ≤55 mg/dL within the next 20 min.

To estimate lag time for each sensor, CGM measurements were linearly interpolated to estimate glucose values at 1-min intervals. The MARD was calculated for every minute of lag
time for each sensor, and the lag time associated with the smallest MARD was assigned as the lag time for that sensor. Mean lag time was calculated for all sensors, and for sensors placed at each wear location.

Device safety was assessed by evaluation of all device-related adverse events. All analyses were performed using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA).

Results

Study population

Baseline demographics are summarized in Table 1. The study enrolled 318 adult participants. More than two-thirds of the participants were overweight or obese, consistent with the prevalence of these conditions among people with diabetes in the United States. The participants attempted to initialize 670 sensors, and of these, 40 failed to return any glucose values. One participant withdrew from the study before YSI measurements, and one did not qualify for clinic sessions due to an associated comorbidity of uncontrolled hypertension. The remaining 316 participants provided data from 308 arm and 311 abdomen devices (79,003 CGM-YSI matched pairs). Of these matched pairs, there were 77,774 in the reportable range of 40–400 mg/dL (39,193 from arm devices and 38,581 from abdomen devices) that were included in the calculation of accuracy metrics.

Overall MARD and agreement rates

The overall MARD for arm-placed sensors was 8.2%, and the overall %15/15, %20/20, and %30/30 agreement rates were 89.6%, 95.3%, and 98.8%, respectively. Similarly, the overall MARD for abdomen-placed sensors was 9.1%, and the overall %15/15, %20/20, and %30/30 were 85.5%, 93.2%, and 98.1%, respectively.

Individual sensor accuracy

Among the 308 sensors worn on the arm, 291 (94.5%) had >80% of CGM-YSI matched pairs that met the %20/20 accuracy criterion. Similarly, among the 311 sensors worn on the abdomen, 272 (87.5%) had >80% of matched pairs that met the %20/20 accuracy criterion. Figure 2 summarizes the performance of all 619 individual sensors. The mean and median per-sensor MARDs were 8.8% and 7.8%, respectively, 442 (71.4%) had MARD values <10%, and 12 (1.9%) had MARD values >20%.

Accuracy across days of wear, glucose ranges, and patient characteristics

Accuracy across clinic days is summarized in Table 2, and accuracy across glucose ranges is summarized in Table 3. In Table 3, MAD is presented in the 40–60 and 61–80 mg/dL ranges; MARD is presented for ranges >80 mg/dL. Accuracy by diabetes type and insulin regimen is summarized in Table 4. Accuracy remained high in both arm- and abdomen-placed sensors across the 10-day wear period through the 12-h grace period, and across glucose ranges. There were no statistically significant differences between G7 accuracy when participants were analyzed by diabetes type and insulin regimen.
Heterogeneity of accuracy was also assessed across the subgroups of gender (male/female) and BMI category (underweight/normal, overweight, obese Class I, obese Class II/III) as defined in Table 1. There were no statistically significant differences in accuracy (results not shown) across these subgroups. Participants in the lowest BMI decile (<22 kg/m²) had a %20/20 agreement rate and MARD of 95.3% and 7.8%, respectively; those in the nine higher BMI deciles (>22 kg/m²) had a %20/20 agreement rate and MARD of 94.1% and 8.8%, respectively.

### Accuracy at Various RoCs

G7 accuracy at different glucose concentration RoCs is summarized in Table 5. The highest %20/20 agreement rates and lowest MARDs occurred when CGM readings were increasing or decreasing by no more than 1 mg/dL per minute. For arm-placed sensors, the MARDs at rapidly decreasing (RoC <-2 mg/dL per minute) or rapidly increasing (RoC >2 mg/dL per minute) were 9.3% and 9.7%, respectively, and the %20/20 agreement rates were 90.1% and 90.3%, respectively. Similarly, for abdomen-placed sensors, MARDs at rapidly decreasing or increasing ROCs were 10.4% and 10.3%, respectively, and %20/20 agreement rates were 87.9% and 89.4%, respectively.

### Threshold and Urgent Low Soon Alert Performance

When the hypoglycemia threshold alert was set to 55 mg/dL, the true alert rates for detection of hypoglycemia <70 mg/dL by sensors worn on the arm and abdomen were 91.3% and 85.2%, respectively. When the hyperglycemia threshold alert was set to 300 mg/dL, the true alert rates for detection of hyperglycemia >250 mg/dL by sensors worn on the arm and abdomen were 99.9% and 99.8%, respectively. Table 6 summarizes G7 alert and detection rates for hypoglycemia and hyperglycemia at various thresholds using more stringent criteria.

Of the 17 Urgent Low Soon alerts arising from arm-placed sensors, 8 (47.1%) were followed within 30 min by YSI value(s) ≤55 mg/dL and 16 (94.1%) were followed within 30 min by YSI value(s) ≤70 mg/dL. Of the 27 Urgent Low Soon alerts arising from abdomen-placed sensors, 11 (40.7%) were followed within 30 min by YSI value(s) ≤55 mg/dL and 18 (66.7%) were followed within 30 min by YSI value(s) ≤70 mg/dL.

### Time Lag

The overall mean (standard error [SE]) time lag for the 619 sensors worn in the study was 3.5 (0.13) min. The mean (SE) time lags for sensors worn on the arm and abdomen were 3.6 (0.20) min and 3.4 (0.19) min, respectively.

### Table 2. Sensor Accuracy Across Days of Sensor Wear

| Placement | Clinic session day | Matched pairs (n) | %15/15 (%) | %20/20 (%) | %30/30 (%) | MARD (%) |
|-----------|-------------------|-------------------|------------|------------|------------|----------|
| Arm (N=308) | Day 1 | 6001 | 76.9 | 87.4 | 95.9 | 11.9 |
| | Day 2 | 8279 | 89.4 | 95.5 | 98.8 | 8.4 |
| | Day 4 | 7312 | 91.8 | 97.2 | 99.6 | 7.2 |
| | Day 7 | 5898 | 93.7 | 97.5 | 99.5 | 7.2 |
| | Day 10 | 5787 | 92.4 | 96.4 | 99.4 | 7.6 |
| | Day 10.5 | 5916 | 93.2 | 97.4 | 99.4 | 6.9 |
| Abdomen (N=311) | Day 1 | 5864 | 73.0 | 84.5 | 94.7 | 12.9 |
| | Day 2 | 8438 | 86.5 | 94.9 | 99.3 | 8.6 |
| | Day 4 | 7624 | 90.9 | 96.6 | 99.3 | 7.7 |
| | Day 7 | 6088 | 89.5 | 95.3 | 98.5 | 8.1 |
| | Day 10 | 5828 | 84.5 | 92.9 | 98.2 | 9.3 |
| | Day 10.5 | 4739 | 86.4 | 93.1 | 97.6 | 8.8 |

MARD, mean absolute relative difference.

### Table 3. Sensor Accuracy Across Continuous Glucose Monitoring Glucose Ranges

| Placement | Glucose range (mg/dL) | Matched pairs (n) | %15/15 (%) | %20/20 (%) | %30/30 (%) | MAD (mg/dL) | MARD (%) |
|-----------|-----------------------|-------------------|------------|------------|------------|------------|----------|
| Arm (N=308) | 40–60 | 2444 | 85.1 | 91.9 | 97.0 | 8.5 | NA |
| | 61–80 | 5485 | 92.6 | 96.5 | 98.9 | 6.3 | NA |
| | 81–180 | 15,319 | 86.2 | 93.6 | 98.3 | NA | 8.9 |
| | 181–300 | 10,465 | 90.3 | 96.0 | 99.3 | NA | 7.2 |
| | 301–400 | 5480 | 96.8 | 99.1 | 99.9 | NA | 5.4 |
| Abdomen (N=311) | 40–60 | 2430 | 77.1 | 85.0 | 94.2 | 10.3 | NA |
| | 61–80 | 5309 | 89.4 | 94.1 | 97.8 | 9.7 | NA |
| | 81–180 | 15,074 | 82.7 | 92.0 | 97.7 | NA | 9.6 |
| | 181–300 | 10,108 | 85.1 | 93.4 | 98.8 | NA | 8.3 |
| | 301–400 | 5654 | 93.5 | 98.6 | 99.8 | NA | 6.2 |

MAD, mean absolute difference; NA, not applicable.
Adverse events and user experience

There were no serious adverse events in the study population. Four participants reported mild to moderate device-related adverse events. One participant experienced moderate erythema at the insertion site (arm) and adhesive areas, one experienced mild skin tearing at the adhesive area (abdomen) as well as mild discomfort during sensor removal, and one experienced moderate discomfort during sensor removal (arm). A total of 241 participants (75.8%) had sensor removal, and one experienced moderate discomfort during sensor removal,164 (68.1%) found G7 easier to insert than their current personal device. Of the participants who expressed a preference for wear location, most (51.7%) indicated a preference for arm wear.

Discussion

The G7 CGM described in this pivotal study was accurate and safe when inserted on either the upper arm or abdomen in adults with diabetes. In-clinic glucose manipulations and frequent blood glucose sampling confirmed accurate readings during euglycemia, hypoglycemia, and hyperglycemia (reflected as time in range [TIR], time below range [TBR], and time above range [TAR]), as well as during rapid glucose concentration change. Even at the highest rates of glucose concentration change, MARD values <10% were observed for arm-placed sensors and were <10.5% for abdomen-placed sensors. There were no safety concerns during the study.

Table 4. Sensor Accuracy by Diabetes Type and Insulin Regimen

| Placement | Diabetes type and insulin regimen | No. of subjects | No. of matched pairs | %15/15 (%) | %20/20 (%) | %30/30 (%) | MARD (%) |
|-----------|----------------------------------|----------------|---------------------|------------|------------|------------|---------|
| Arm       | Type 1                           | 252            | 31,948              | 89.8       | 95.4       | 98.8       | 8.2     |
| (N=308)   | Type 2—IIT                        | 46             | 6005                | 88.8       | 94.7       | 98.7       | 8.0     |
|           | Type 2—NIIT                       | 10             | 1240                | 87.7       | 96.0       | 99.0       | 9.2     |
| Abdomen   | Type 1                           | 253            | 31,109              | 85.0       | 92.5       | 97.9       | 9.3     |
| (N=311)   | Type 2—IIT                        | 48             | 6260                | 87.6       | 95.8       | 99.1       | 8.6     |
|           | Type 2—NIIT                       | 10             | 1212                | 87.8       | 97.2       | 99.6       | 7.6     |

IIT, intensive insulin therapy; NIIT, nonintensive insulin therapy.

The MARD values of 8.2% (arm) and 9.1% (abdomen) were similar to or better than accuracy measurements of other commercially available CGM systems.8–10 Few studies have directly compared CGM accuracy at different anatomical locations. For example, Steineck et al.,11 in a study of the G4 Platinum system (Dexcom), reported MARD estimates of 12.0% for arm-placed and 12.3% for abdomen-placed sensors, suggesting slightly better accuracy for the arm. In a study of pregnant women with diabetes using the G6 system,12 the MARD values for sensors worn on the arm, abdomen, and buttock were 8.7%, 11.5%, and 11.2%, respectively.

An earlier in silico study suggested that MARD values <10% allow for insulin dosing decisions without reliance on blood glucose test results.13 In this study, single-digit MARD values were observed for >70% of the individual sensors. The prevalence of sensors with MARD values ≥20% was lower than was observed in an earlier accuracy study of G6 sensors;6 the basis of anomalously poor accuracy in a small proportion of sensors is unknown. Consistent with earlier studies of systems from Dexcom and other manufacturers, slightly lower accuracy was observed immediately after sensor insertion,14 during hypoglycemia,15 and at rapid rates of glucose concentration change.16

Time delays between perturbations in YSI and G7 readings were also similar to or better than time delays in prior generation Dexcom CGMs. In 2009, Bailey et al.17 estimated the lag time of Dexcom’s SEVEN Plus system as 11 min, and in 2020, Guillot et al.18 reported a lag time of 13 min for G6 during exercise. Using data from the pivotal accuracy study, Calhoun et al.19 estimated the G6 lag time as 3.7 min, and noted that 23% of the G6 sensors had lag times of <1 min. The mean lag time of 3.5 min reported here for G7 is likely attributable to improvements in both the hardware and signal processing algorithm and may have implications for automated insulin delivery systems.

Several aspects of G7 hardware and software are different from G6. The G7 sensor wire is shorter than that of G6 and is inserted at a steeper (90°) angle. The redesigned applicator allows for sensor deployment with one hand, and most participants found G7 easier to insert than their prior CGM system. Integration of the sensor and transmitter eliminates the need for using a transmitter across multiple sensor sessions (as is the case for G6).

The G7 adhesive patch is smaller, about half the size of the G6 adhesive patch. In addition, data are available from G7 within 27 min of insertion versus a 2-h startup time for G6, and G7 data continue to be available for a 12-h “grace period” at the end of a sensor session. As is the case with G6, calibration of G7 sensors remains optional. Unlike G6, G7

---

Table 5. Sensor Accuracy at Various Rates of Glucose Concentration Change

| Placement | CGM rate range (mg/dL per minute) | Matched pairs (n) | %20/20 (%) | MARD (%) |
|-----------|----------------------------------|------------------|------------|---------|
| Arm       | <-2                              | 1006             | 90.1       | 9.3     |
| (N=308)   | -2 to <-1                        | 3266             | 94.0       | 8.4     |
|           | -1 to 0                          | 15,220           | 96.2       | 8.1     |
|           | 0 to 1                           | 12,657           | 96.5       | 7.8     |
|           | >1 to 2                          | 3742             | 94.3       | 8.3     |
|           | >2                               | 2411             | 90.3       | 9.7     |
| Abdomen   | <-2                              | 895              | 87.9       | 10.4    |
| (N=311)   | -2 to <-1                        | 2997             | 91.4       | 9.3     |
|           | -1 to 0                          | 15,350           | 94.3       | 9.0     |
|           | 0 to 1                           | 12,486           | 93.6       | 9.0     |
|           | >1 to 2                          | 3599             | 93.5       | 8.7     |
|           | >2                               | 2337             | 89.4       | 10.3    |

CGM, continuous glucose monitoring.
allows for temporary silencing of all audible alerts, including Urgent Low. Taken together, these attributes are anticipated to provide for a better end-user experience with G7 and help reduce diabetes burden.

The main strength of the study was the large number of devices, participants, and investigational sites, which provided many matched pairs. An additional strength was the in-clinic glucose manipulations that allowed for accuracy determinations in different glycemic ranges and at various rates of glucose concentration change. The study also allowed device placement on the abdomen or arm, which reflects real-world placement practices. The preference for arm over abdomen wear observed here and in an earlier report of Instagram photographs\(^20\) may reflect disadvantages of abdomen wear in clinical use. The study also allowed device placement on the abdomen or arm, which reflects real-world placement practices. The preference for arm over abdomen wear observed here and in an earlier report of Instagram photographs\(^20\) may reflect disadvantages of abdomen wear such as jostling or compression by clothing or seat belts.

The study excluded children and adolescents; data from this population will be reported separately. Participants were predominantly White, and two-thirds were overweight or obese, which is consistent with attributes reported for adult T1D Exchange registry participants\(^21\) and with the high prevalence of overweight and obesity in adults with T2D. The study was not designed to evaluate clinical outcomes such as HbA1c reduction, or changes to metrics such as TIR, TBR, and TAR. Because the alert functions were disabled during the study, real-world alert performance attributes (especially for the Urgent Low Soon alert) may differ from the rates reported here. Performance and outcomes will be evaluated in subsequent trials and retrospective analyses of real-world use.

### Conclusion

This study demonstrates that the G7 CGM is accurate and safe to use for up to 10.5 days in adults with diabetes when worn on either the arm or abdomen. G7 is significantly smaller than G6 (by 60%) and introduces new features such as sensor/transmitter integration with a simplified insertion process. The enhanced features of G7 may increase clinical adoption, encourage sustained use, and reduce the burden of diabetes management.

### Acknowledgments

The authors thank the patients who participated in the study and the research staff at the investigational centers. The authors also thank Xiaohe Zhang, Sharon Gao, and Christy Chao (Dexcom, Inc.) for their help in preparation of the article. Dexcom is a registered trademark of Dexcom, Inc., in the United States and may be in other countries.

### Author Disclosure Statement

S.K.G. reports consultant fees from Medtronic, Novo Nordisk, Zealand, Lifescan, Roche, and Lily; and research grants through the University of Colorado from Lilly, Novo Nordisk, Medtronic, Dexcom, T1D Exchange, Helmsley Trust, NIDDK, and JDRF. M.K. reports research support from Medtronic, SARO, Pfizer, Dexcom, Abbott, Regenacy, Metacrine, Lumos, Ascendis, Sagimet, MannKind, Aeterna-Zentaris, Bio89, Gilead, Senseonics, KOWA, Allergan, NGM, Tolerion, Lilly, Vertex, and Diamyd; and has a consulting agreement with Quest Diagnostics.

K.C. receives research support provided to her institution from Dexcom, Abbott Labs, Abbott Diabetes, Medtronic, Eyenuk, Laxmi, Novo Nordisk, and Insulet and has received consulting fees from Dexcom. T.S.B. reports research support from Abbott Diabetes, Abbott Rapid Diagnostics, Biolinq, Capillary Biomedical, Dexcom, Eli Lilly, Kowa, Livongo, Mannkind, Medtronic, Novo Nordisk, REMD, Sanofi, Sanvita, Senseonics, Viacyte, vTV Therapeutics, and Zealnd Pharma; consulting honoraria from Abbott, CeQur, Lifescan, Mannkind, Medtronic, Novo, and Sanofi; and speaker honoraria from BD, Medtronic, and Sanofi.

H.K.A. received research grants through the University of Colorado from Senseonics, Dexcom, Eli Lilly, REMD Biotherapeutics, IM Therapeutics, Institute for the Advancement of Food and Nutrition Sciences, and Mannkind; and honorarium from the American Diabetes Association for speaking and consulting. M.P.C., on behalf of Diablo Clinical Research, reports research support from Abbott Diabetes Care, Biolinq, Dexcom, Medtronic, SanVita, Senseonics, Abbott

---

**Table 6. Hypoglycemic and Hyperglycemic Alerts and Detections at Various Thresholds**

| Condition   | Placement | Alert or detection level (mg/dL) | No. of alerts | True alert rate (%) | No. of detections | True detection rate (%) |
|-------------|-----------|----------------------------------|---------------|---------------------|------------------|-------------------------|
| Hypoglycemia| Arm       | 300                              | 9636          | 90.1                | 16,454           | 97.8                    |
|             | (N=308)   | 240                              | 11,139        | 94.4                | 23,854           | 98.0                    |
|             | Abdomen   | 200                              | 14,380        | 96.8                | 24,147           | 98.5                    |
|             | (N=311)   | 180                              | 16,653        | 97.0                | 24,147           | 98.5                    |
| Hyperglycemia| Arm       | 120                              | 8884          | 91.6                | 11,244           | 95.9                    |
|             | (N=308)   | 200                              | 14,521        | 97.1                | 6630             | 88.7                    |
|             | Abdomen   | 120                              | 29,941        | 96.3                | 14,521           | 97.1                    |
|             | (N=311)   | 180                              | 20,970        | 95.6                | 11,244           | 95.9                    |

All participants were considered in the analysis; however, not all participants experienced a hypoglycemic or hyperglycemic event.
Point of Care, Ascensia, Novo Nordisk, Merck, Boehringer Ingelheim, and Helixmith. S.A.B. reports research support through the University of Virginia from Tandem Diabetes Care, Insulet, Tolerion, Roche Diagnostics, and Dexcom. J.B.W., A.K.B., J.L.R., and S.E.B are employees and stockholders of Dexcom, Inc.

Funding Information
This study was supported by a grant from Dexcom, Inc.

Supplementary Material
Supplementary Table S1

References
1. Martens T, Beck RW, Bailey R, et al.: Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 2021;325:2262–2272.
2. Beck RW, Riddlesworth T, Ruedy K, et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317:371–378.
3. Lind M, Polonsky W, Hirsch IB, et al.: Continuous glucose monitoring vs conventional therapy for glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA 2017;317:379–387.
4. Karter AJ, Parker MM, Moffet HH, et al.: Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with type 1 diabetes: hypoglycaemia remains the weak spot. Diabetes Obes Metab 2019;21:1043–1048.
5. Pleus S, Schoemaker M, Morgenstern K, et al.: Rate-of-change dependence of the performance of two CGM systems during induced glucose swings. J Diabetes Sci Technol 2015;9:801–807.
6. Bailey T, Zisser H, Chang A: New features and performance of a next-generation SEVEN-day continuous glucose monitoring system with short lag time. Diabetes Technol Ther 2009;11:749–755.
7. Guillot F, Jacobs PG, Wilson LM, et al.: Accuracy of the Dexcom G6 Glucose Sensor during aerobic, resistance, and interval exercise in adults with type 1 diabetes. Biosensors (Basel) 2020;10:138.
8. Calhoun P, Puhr S, Welsh JB, et al.: Lag time of a sixth-generation continuous glucose monitoring system. J Diabetes Sci Technol 2018;13:254–258.
9. Abbott: FreeStyle Libre 2 Flash Glucose Monitoring System User’s Manual. ART44417-001 Rev. A. https://freestyleserver.com/Payloads/IFU/2021/q4/ART44417-001_rev-A-WEB.pdf (accessed December 13, 2021).
10. Medtronic: Guardian Connect System User Guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/GuardianT%20Connect%20CGM%20System%20User%20Guide.PDF (accessed December 13, 2021).
11. Steineck IK, Mahmoudi Z, Ranjan A, et al.: Comparison of continuous glucose monitoring accuracy between abdominal and upper arm insertion sites. Diabetes Technol Ther 2019;21:295–302.
12. Castorino K, Polsky S, O’Malley G, et al.: Performance of the Dexcom G6 continuous glucose monitoring system in pregnant women with diabetes. Diabetes Technol Ther Dec 2020;22:943–947.
13. Kovatchev BP, Patek SD, Ortiz EA, Breton MD: Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 2015;17:177–186.
14. Freeckmann G, Link M, Kamecke U, et al.: Performance and usability of three systems for continuous glucose monitoring in direct comparison. J Diabetes Sci Technol 2019;13:890–898.
15. Moser O, Pandis M, Aberer F, et al.: A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot. Diabetes Obes Metab 2019;21:1043–1048.
16. Litchman ML, Wawrzynski SE, Woodruff WS, et al.: Continuous glucose monitoring in the real world using photosurveillance of #Dexcom on Instagram: exploratory Mixed Methods Study. JMIR Public Health Surveill 2019;5:e11024.
17. Foster NC, Beck RW, Miller KM, et al.: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther 2019;21:66–72.

Address correspondence to:
Satish K. Garg, MD
Department of Medicine and Pediatrics
Barbara Davis Center for Diabetes
University of Colorado Denver
1775 Aurora Court
Aurora, CO 80045
USA
E-mail: satish.garg@cuanschutz.edu